NCT02953743 is a Phase 1 clinical trial of Lenvatinib in Unresectable Hepatocellular Carcinoma (HCC), sponsored by Eisai Co., Ltd..

Who is sponsoring NCT02953743?

NCT02953743 is sponsored by Eisai Co., Ltd..

What drugs are being tested in NCT02953743?

Interventions in NCT02953743: Lenvatinib.

What condition does NCT02953743 study?

NCT02953743 studies Unresectable Hepatocellular Carcinoma (HCC).

Is NCT02953743 still recruiting?

NCT02953743 is currently completed. Last updated 1 April 2021.

Last reviewed 2021-04-01 · How we verify

NCT02953743

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)

Completed Phase 1 Last updated 1 April 2021

What this trial tests

Phase 1 trial testing Lenvatinib in Unresectable Hepatocellular Carcinoma (HCC) in 25 participants. Completed in 28 December 2020.

Timeline

1 September 2016

Primary endpoint
28 June 2017

28 December 2020

Quick facts

Lead sponsor	Eisai Co., Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	1 September 2016
Primary completion	28 June 2017
Estimated completion	28 December 2020
Sites	3 locations across China

Drugs / interventions tested

Lenvatinib (LENVATINIB) — full drug profile →

Conditions studied

Unresectable Hepatocellular Carcinoma (HCC) — all drugs for Unresectable Hepatocellular Carcinoma (HCC) →

Sponsor

Eisai Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Unresectable Hepatocellular Carcinoma (HCC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary purpose of this study is to assess the single- and multiple-dose pharmacokinetic (PK) profile of lenvatinib in Chinese participants with unresectable Hepatocellular Carcinoma (HCC).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Lenvatinib

Trials testing the same drug.

NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07518706 — Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin · Phase 2 · not yet recruiting
NCT07493668 — Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy · Phase 2 · not yet recruiting

Other recruiting trials for Unresectable Hepatocellular Carcinoma (HCC)

Currently open trials in the same condition.

NCT07391839 — MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma. · Phase 1 · recruiting
NCT07408804 — Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib M · NA · recruiting

Other Eisai Co., Ltd. trials

Trials by the same sponsor.

NCT07515014 — A Study of E6742 in Participants With Systemic Lupus Erythematosus · Phase 2 · not yet recruiting
NCT06793709 — A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast G · recruiting
NCT06657378 — A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized T · recruiting
NCT06322667 — A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab · recruiting
NCT05633108 — A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02953743 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eisai Co., Ltd.
Last refreshed: 1 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02953743.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing